News and Announcements
Asianomics Outlook: Surf’s Up or Tide Turning?
- Published September 25, 2012 9:51AM UTC
- Publisher Wholesale Investor
- Categories Capital Insights
By: Dr Jim Walker
The outlook covers the following topics:
- Asianomics Global Investment Strategy (1st Half 2012)
- America and Eurozone round-up
- Bank credit relatives in the US and Europe
- It’s not just about public debt
- No recession looming in the US
- Asianomics Asian investment strategy (1st Half 2012)
- Asian round-up: Upside or downside?
- Despite Japan’s woes the yen looks good
- Asian industrial production trending down
- Significant monetary easing is not justified
- China landing: None or hard?
- China’s monetary explosion (real inflation)
- Investment is the cyclical driver
- India’s Hubris: Payback time
- Currency rebounds while production languishes
To read a full article, please download a document below.
Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
